Proof of efficacy trials: cross-over versus parallel-group

Area of Science:

• Clinical Trials Methodology
• Pharmacological Research
• Neurology

Background:

• Recent antiepileptic drug (AED) trials predominantly use parallel-group designs.
• Crossover trial designs, though less common, possess distinct advantages that warrant re-evaluation.

Purpose of the Study:

• To reappraise the role and advantages of crossover trial designs in the context of new antiepileptic drug development.
• To compare the efficiencies and limitations of crossover versus parallel-group trial designs for antiepileptic drugs.

Main Methods:

• Comparative analysis of crossover and parallel-group trial designs in antiepileptic drug (AED) research.
• Evaluation of statistical power, patient recruitment, cost-effectiveness, and ethical considerations for both designs.

Main Results:

• Crossover designs require fewer patients, reduce costs, and enhance detection of drug interactions by using patients as their own controls.
• Parallel-group designs offer greater versatility for newly diagnosed patients and multiple treatment arms but necessitate larger patient cohorts and multicenter approaches.

Conclusions:

• Crossover designs are efficient for proof-of-principle and add-on proof-of-efficacy trials of new antiepileptic drugs.
• Parallel-group designs are better suited for subsequent evaluations and trials requiring flexibility, such as those involving newly diagnosed epilepsy patients.